{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:56:31Z","timestamp":1790614591115,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13300-026-01848-6","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:04:53Z","timestamp":1773821093000},"page":"587-602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Cohort Study of Semaglutide in Adults with Type\u00a02 Diabetes Using an Electronic Health Records Database in Tianjin, China"],"prefix":"10.1007","volume":"17","author":[{"given":"Shanshan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"1848_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 11th Edition. 2025. www.diabetesatlas.org. Accessed Nov 25, 2025."},{"issue":"12","key":"1848_CR2","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1016\/S2468-2667(24)00251-2","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu Y, Lu J, Li M, et al. Diabetes in China part 2: prevention, challenges, and progress. Lancet Public Health. 2024;9(12):e1098\u2013104.","journal-title":"Lancet Public Health"},{"issue":"1","key":"1848_CR3","first-page":"16","volume":"17","author":"Chinese Society of Diabetes","year":"2024","unstructured":"Chinese Society of Diabetes. Guidelines for the prevention and treatment of diabetes in China (2024 edition). Chin J Diabetes. 2024;17(1):16\u2013139.","journal-title":"Chin J Diabetes"},{"issue":"Suppl 1","key":"1848_CR4","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc24-S006","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes - 2024. Diabetes Care. 2024;47(Suppl 1):S111\u201325.","journal-title":"Diabetes Care"},{"issue":"3","key":"1848_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193442","volume":"13","author":"Y Tekalegn","year":"2018","unstructured":"Tekalegn Y, Addissie A, Kebede T, Ayele W. Magnitude of glycemic control and its associated factors among patients with type\u00a02 diabetes at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. PLoS ONE. 2018;13(3):e0193442.","journal-title":"PLoS ONE"},{"key":"1848_CR6","unstructured":"US Food and Drug Administration (FDA). Ozempic\u00ae Prescribing Information 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf. Accessed Nov 25, 2025."},{"key":"1848_CR7","unstructured":"National Medical Products Administration. Imported drug information of SJ20210015: semaglutide injection. https:\/\/www.nmpa.gov.cn\/datasearch\/search-info.html?nmpa=aWQ9NWU4NjZlNTE4Njg3YjQxMzM4MzUwNGQzMDVkNTA0YmImaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4NjY1NzExODAw. Accessed Nov 25, 2025."},{"issue":"4","key":"1848_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type\u00a02 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase\u00a03a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1848_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type\u00a02 diabetes (SUSTAIN 2): a 56-week, double-blind, phase\u00a03a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1848_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type\u00a02 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"issue":"5","key":"1848_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type\u00a02 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase\u00a03a trial. Lancet Diabetes Endocrinol. 2017;5(5):355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1848_CR12","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type\u00a02 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"1848_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1848_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type\u00a02 diabetes (SUSTAIN 7): a randomised, open-label, phase\u00a03b trial. Lancet Diabetes Endocrinol. 2018;6(4):275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1848_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type\u00a02 diabetes (SUSTAIN 8): a double-blind, phase\u00a03b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1848_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type\u00a02 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1848_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type\u00a02 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139.","journal-title":"Diabetes Metab"},{"issue":"2","key":"1848_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type\u00a02 diabetes. Diabetes Obes Metab. 2018;20(2):378\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1848_CR19","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/dom.13218","volume":"20","author":"K Kaku","year":"2018","unstructured":"Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type\u00a02 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20(5):1202\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1848_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type\u00a02 diabetes in SUSTAIN China: a 30-week, double-blind, phase\u00a03a, randomized trial. Diabetes Obes Metab. 2021;23(2):404\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1848_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.36469\/jheor.2024.124111","volume":"11","author":"NN Gronroos","year":"2024","unstructured":"Gronroos NN, Swift C, Frazer MS, et al. Real-world HbA1c changes among type\u00a02 diabetes mellitus patients initiating treatment with a 1.0\u00a0mg weekly dose of semaglutide for diabetes. J Health Econ Outcomes Res. 2024;11(2):118\u201324.","journal-title":"J Health Econ Outcomes Res"},{"issue":"11","key":"1848_CR22","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","volume":"12","author":"P Holmes","year":"2021","unstructured":"Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type\u00a02 diabetes: results from the SURE UK multicentre, prospective, observational study. Diabetes Ther. 2021;12(11):2891\u2013905.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1848_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/a-2007-2061","volume":"131","author":"M Menzen","year":"2023","unstructured":"Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S. Real-world use of once-weekly semaglutide in type\u00a02 diabetes: results from SemaglUtide Real-world Evidence (SURE) Germany. Exp Clin Endocrinol Diabetes. 2023;131(4):205\u201315.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"1848_CR24","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/dom.15020","volume":"25","author":"R Napoli","year":"2023","unstructured":"Napoli R, Berra C, Catarig AM, et al. Once-weekly semaglutide use in patients with type\u00a02 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25(6):1658\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1848_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-024-01661-z","volume":"16","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Fan Y, Liu X, et al. Treatment patterns and glycaemic control between 2015 and 2019 in Tianjin, China: a real-world study of adults with type\u00a02 diabetes. Diabetes Ther. 2025;16(1):1\u201314.","journal-title":"Diabetes Ther"},{"issue":"11","key":"1848_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015240","volume":"7","author":"AD Napier","year":"2017","unstructured":"Napier AD, Nolan JJ, Bagger M, Hesseldal L, Volkmann AM. Study protocol for the Cities Changing Diabetes programme: a global mixed-methods approach. BMJ Open. 2017;7(11):e015240.","journal-title":"BMJ Open"},{"issue":"11","key":"1848_CR27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1111\/dom.14117","volume":"22","author":"RE Brown","year":"2020","unstructured":"Brown RE, Bech PG, Aronson R. Semaglutide once weekly in people with type\u00a02 diabetes: real-world analysis of the Canadian LMC diabetes registry (SPARE study). Diabetes Obes Metab. 2020;22(11):2013\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1848_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002619","volume":"10","author":"JF Yale","year":"2022","unstructured":"Yale JF, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type\u00a02 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022;10(2):e002619.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"1848_CR29","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/dom.15552","volume":"26","author":"C Shi","year":"2024","unstructured":"Shi C, Tan Y, Hu S, et al. Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type\u00a02 diabetes: a retrospective, observational post-marketing study. Diabetes Obes Metab. 2024;26(6):2513\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"1848_CR30","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.jacc.2024.08.022","volume":"84","author":"S Verma","year":"2024","unstructured":"Verma S, Colhoun HM, Dicker D, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT). J Am Coll Cardiol. 2024;84(17):1678\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1848_CR31","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","volume":"45","author":"P Marzullo","year":"2022","unstructured":"Marzullo P, Daffara T, Mele C, et al. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. J Endocrinol Invest. 2022;45(8):1587\u201398.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1848_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s13300-020-00984-x","volume":"12","author":"AB Jain","year":"2021","unstructured":"Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type\u00a02 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther. 2021;12(2):527\u201336.","journal-title":"Diabetes Ther"},{"key":"1848_CR33","first-page":"505","volume":"10","author":"K He","year":"2014","unstructured":"He K, Shi JC, Mao XM. Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients. Ther Clin Risk Manag. 2014;10:505\u201311.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"1848_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cmet.2023.01.004","volume":"35","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Coughlan MT, Cooper ME. The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type\u00a02 diabetes. Cell Metab. 2023;35(2):253\u201373.","journal-title":"Cell Metab"},{"issue":"10","key":"1848_CR35","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1111\/dom.15794","volume":"26","author":"JF Yale","year":"2024","unstructured":"Yale JF, Major-Pedersen A, Catarig AM, Jain R, Menzen M, Holmes P. Real-world safety profile of once-weekly semaglutide in people with type\u00a02 diabetes: analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme. Diabetes Obes Metab. 2024;26(10):4429\u201340.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01848-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:16:19Z","timestamp":1776845779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01848-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1848"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01848-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ping Hu and Zewei Shen are employees of Novo Nordisk A\/S, the sponsors of this study, and Zewei Shen also owns shares in Novo Nordisk A\/S. Shanshan Wang and Liming Chen report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices. Patient consent was not required as the analyses used retrospective de-identified data without access to personal identifying information. The study protocol and the application for a waiver to informed consent were approved by the independent ethics committee and institutional review board. We can confirm that we, the authors, have permission to use the Tianjin Healthcare and Medical Big Data Platform to access and use the data for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}